Medical Condition News

RSS

Emotional well-being predicts adolescents' physical health: Study

Happier youths are also healthier youths, according to Emily Shaffer-Hudkins and her team, from the University of South Florida in the US. Adolescents' positive emotions and moods, as well as their satisfaction with life, could be more important than their anxiety or depression levels for predicting their physical health, they argue.

9 Jul 2010

Australian, Vietnamese researchers develop simple tool for identifying individuals at high risk of Type 2 diabetes

Australian and Vietnamese researchers have estimated the current prevalence of Type 2 diabetes in Vietnam, and have developed a simple tool for identifying individuals at high risk.

9 Jul 2010

Jasmine can be used instead of sleeping pills or mood enhancers: Study

Instead of a sleeping pill or a mood enhancer, a nose full of jasmine from Gardenia jasminoides could also help: in collaboration with Dr. Olga Sergeeva and Prof. Helmut Hass from the Heinrich Heine University in Düsseldorf, researchers from Bochum led by Prof. Dr. Dr. Dr. Hanns Hatt have discovered that the two fragrances Vertacetal-coeur (VC) and the chemical variation (PI24513) have the same molecular mechanism of action and are as strong as the commonly prescribed barbiturates or propofol.

9 Jul 2010

NeuroPace submits PMA to FDA for world's first responsive neurostimulation system

NeuroPace, Inc. today announced that it has submitted its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its RNS® System, a novel investigational device that utilizes responsive neurostimulation to monitor and interrupt abnormal electrical activity in the brain before seizures occur. The PMA application is for an indication to treat people with medically refractory partial onset epilepsy originating from one or two locations in the brain.

9 Jul 2010

FDA approves Roxane's Naratriptan Tablets ANDA

Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Naratriptan Tablets USP, 1mg and 2.5mg by the U.S. Food and Drug Administration. The product is available in bottles of 9 for immediate shipment to wholesalers and pharmacies nationwide.

9 Jul 2010

Qualaquin for treatment of night time leg cramps leads to serious side effects, FDA warns

The U.S. Food and Drug Administration today warned that the unapproved use of the malaria drug Qualaquin (quinine sulfate) to treat night time leg cramps has resulted in serious side effects and prompted the manufacturer to develop a risk management plan aimed at educating health care professionals and patients about the potential risks.

9 Jul 2010

BioCurex reports first set of results supporting RECAF blood test for monitoring cancer therapy

BioCurex Inc. today announced its first set of results supporting the use of the BioCurex RECAF blood test to monitor cancer therapy. The test included samples from 27 human patients with early stages of breast cancer that were tested before and after surgery. As a control, 15 samples from healthy individuals were also tested.

9 Jul 2010

Bayer HealthCare to present BAY86-6150 rFVIIa Phase I clinical data at XXIX WFH International Congress

Phase I clinical data for BAY86-6150, a novel recombinant factor VIIa protein (rFVIIa) being developed by Bayer HealthCare, will be presented at the XXIX International Congress of the World Federation of Hemophilia (WFH) to be held in Buenos Aires, Argentina from Saturday, July 10-Wednesday, July 14.

9 Jul 2010

pSivida submits MAA for Iluvien to UK MHRA

pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has submitted a Marketing Authorization Application (MAA) to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (UK) for Iluvien®.

8 Jul 2010

Study demonstrates causal relationship between onset of Creutzfeldt-Jakob disease and general surgery

A new study spearheaded by Spanish scientists demonstrates a causal relationship between the onset of Creutzfeldt-Jakob disease (CJD), caused by a protein called a prion, and general surgery. CJD manifests itself in hereditary acquired; and sporadic forms, or for unknown reasons, which accounts for the majority of cases.

8 Jul 2010

Rockwell Medical completes End of Phase II meeting with FDA regarding SFP

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease, chronic kidney disease, and iron deficiency anemia, announced today that it has successfully completed an End of Phase II meeting with the U.S. Food and Drug Administration regarding the Company's lead drug candidate Soluble Ferric Pyrophosphate, a novel continuous iron-replacement therapy designed to treat iron deficiency anemia in hemodialysis patients.

8 Jul 2010

Fibrocell Science completes enrollment in azficel-T histology study

Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today the completion of enrollment of and first treatment visits for participants in its histology study (IT-H-001) of azficel-T. An autologous cell therapy, azficel-T is currently under review by the U.S. Food and Drug Administration for the treatment of moderate to severe nasolabial fold wrinkles.

8 Jul 2010

First patient enrolled in Boston Scientific's MultiSENSE clinical trial

Boston Scientific Corporation today announced enrollment of the first patient in its MultiSENSE clinical trial. The trial is designed to evaluate multiple physiologic sensors in the Company's COGNIS cardiac resynchronization therapy defibrillators. Boston Scientific plans to use the trial data to help develop a clinical alert that identifies the early onset of worsening heart failure.

8 Jul 2010

Alimera Sciences submits MAA for Iluvien to MHRA

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals has submitted a Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency in the United Kingdom for Iluvien (fluocinolone acetonide intravitreal insert).

8 Jul 2010

Study: 30-minute massage improves psychological, physiological state of patients with tension headache

Researchers at the University of Granada -in collaboration with the Clinical Hospital San Cecilio and the University Rey Juan Carlos- have proven that the psychological and physiological state of patients with tension headache improves within 24 hours after receiving a 30-minute massage.

8 Jul 2010

VDF announces launch of new PAD exercise training toolkit for health professionals

The Vascular Disease Foundation announced the launch of its new "Peripheral Arterial Disease Exercise Training Toolkit: A Guide for Health Care Professionals." This toolkit was developed jointly by the Vascular Disease Foundation and the American Association of Cardiovascular and Pulmonary Rehabilitation and may be accessed online at www.vdf.org/rehab-toolkit/index.php

8 Jul 2010

Kiadis Pharma receives FDA approval for IND to start pivotal clinical study for ATIR

Biopharmaceutical Company Kiadis Pharma announced today that it has received approval for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start the pivotal clinical study for its product ATIR™ in the United States. Kiadis Pharma is currently enrolling patients in a multinational, pivotal clinical study at hospitals in Europe and Canada. With the approval of the IND, US hospitals will also participate in this study.

8 Jul 2010

USF granted patent for cell transplantation procedure

The University of South Florida's Department of Neurosurgery and Brain Repair has been granted a patent for a cell transplantation procedure combining human umbilical cord blood cells and a sugar-alcohol compound called "mannitol" that may make a big difference in treating life-threatening neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis and stroke, among others.

8 Jul 2010

Profil Institute for Clinical Research to support ADA's Step Out: Walk to Fight Diabetes

Profil Institute for Clinical Research, Inc., a company specializing in early phase clinical trials for diabetes and obesity, announced today that Dr. Marcus Hompesch, the company's President and CEO, will serve as San Diego's 2010 Corporate Chairman for Step Out: Walk to Fight Diabetes, the American Diabetes Association's largest fund-raising event.

8 Jul 2010

New surgery can improve outcomes in patients with severe adult flat foot deformity

A surgery developed at Hospital for Special Surgery can improve patient outcomes in individuals with severe adult flat foot deformity, a problem that is increasingly being seen in hospitals across the country. Patients who undergo the new surgery have better long-term outcome and mobility than those who undergo traditional surgery.

8 Jul 2010

Medical Condition News

Emotional well-being predicts adolescents' physical health: Study

Australian, Vietnamese researchers develop simple tool for identifying individuals at high risk of Type 2 diabetes

Jasmine can be used instead of sleeping pills or mood enhancers: Study

NeuroPace submits PMA to FDA for world's first responsive neurostimulation system

FDA approves Roxane's Naratriptan Tablets ANDA

Qualaquin for treatment of night time leg cramps leads to serious side effects, FDA warns

BioCurex reports first set of results supporting RECAF blood test for monitoring cancer therapy

Bayer HealthCare to present BAY86-6150 rFVIIa Phase I clinical data at XXIX WFH International Congress

pSivida submits MAA for Iluvien to UK MHRA

Study demonstrates causal relationship between onset of Creutzfeldt-Jakob disease and general surgery

Rockwell Medical completes End of Phase II meeting with FDA regarding SFP

Fibrocell Science completes enrollment in azficel-T histology study

First patient enrolled in Boston Scientific's MultiSENSE clinical trial

Alimera Sciences submits MAA for Iluvien to MHRA

Study: 30-minute massage improves psychological, physiological state of patients with tension headache

VDF announces launch of new PAD exercise training toolkit for health professionals

Kiadis Pharma receives FDA approval for IND to start pivotal clinical study for ATIR

USF granted patent for cell transplantation procedure

Profil Institute for Clinical Research to support ADA's Step Out: Walk to Fight Diabetes

New surgery can improve outcomes in patients with severe adult flat foot deformity

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News